No headlines found.
Business Wire (Thu, 29-Jan 4:05 PM ET)
Business Wire (Mon, 12-Jan 8:00 AM ET)
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Mon, 5-Jan 7:00 AM ET)
Business Wire (Tue, 30-Dec 4:05 PM ET)
KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer
Business Wire (Tue, 16-Dec 4:05 PM ET)
Business Wire (Mon, 17-Nov 4:05 PM ET)
KORU Medical Systems to Participate in Upcoming Investor Conferences
Business Wire (Thu, 13-Nov 8:00 AM ET)
KORU Medical Systems Announces 27% Q3 Revenue Growth and Raises 2025 Revenue Guidance
Business Wire (Wed, 12-Nov 4:05 PM ET)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Koru Medical Systems trades on the NASDAQ stock market under the symbol KRMD.
As of February 6, 2026, KRMD stock price climbed to $4.97 with 106,851 million shares trading.
KRMD has a beta of 1.40, meaning it tends to be more sensitive to market movements. KRMD has a correlation of 0.17 to the broad based SPY ETF.
KRMD has a market cap of $230.22 million. This is considered a Small Cap stock.
Last quarter Koru Medical Systems reported $10 million in Revenue and $.00 earnings per share. This beat revenue expectation by $714,760 and exceeded earnings estimates by $.03.
In the last 3 years, KRMD traded as high as $6.61 and as low as $1.86.
The top ETF exchange traded funds that KRMD belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
KRMD has underperformed the market in the last year with a price return of +1.4% while the SPY ETF gained +15.2%. However, in the short term, KRMD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +23.3% vs +2.0% return in SPY. But in the last 2 weeks, KRMD shares have been beat by the market, returning -12.5% compared to an SPY return of 0.0%.
KRMD support price is $4.65 and resistance is $5.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KRMD shares will trade within this expected range on the day.